<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964716</url>
  </required_header>
  <id_info>
    <org_study_id>B4671001</org_study_id>
    <secondary_id>2012-000482-21</secondary_id>
    <nct_id>NCT01964716</nct_id>
  </id_info>
  <brief_title>13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.</brief_title>
  <official_title>A Phase 3, Randomized, Open-label Trial To Evaluate The Safety, Tolerability And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials Given With Routine Pediatric Vaccinations In Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the immune responses of the infants who have been given 13vPnC in the
      mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in
      the single-dose syringe formulation.

      It will also evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in all
      infants who are vaccinated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (&gt;=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here &quot;n&quot;= participants with valid and determinate IgG concentration to the given serotype.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series for Each Vaccine Group</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Antibody GMC for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations. Here &quot;n&quot;= participants with valid and determinate IgG concentration to the given serotype.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Local Reaction Within 5 Days After Dose 1 in MDV and SDS Group</measure>
    <time_frame>Within 5 days after Dose 1(Day 2 to Day 6) of the infant series</time_frame>
    <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Local Reaction Within 5 Days After Dose 2 in MDV and SDS Group</measure>
    <time_frame>Within 5 days after Dose 2 (Day 2 to Day 6) of the infant series</time_frame>
    <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Local Reaction Within 5 Days After Dose 3 in MDV and SDS Group</measure>
    <time_frame>Within 5 days after Dose 3 (Day 2 to Day 6) of the infant series</time_frame>
    <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Systemic Events Within 5 Days After Dose 1 in MDV and SDS Group</measure>
    <time_frame>Within 5 days after Dose 1 (Day 2 to Day 6) of infant series</time_frame>
    <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Systemic Events Within 5 Days After Dose 2 in MDV and SDS Group</measure>
    <time_frame>Within 5 days after Dose 2 (Day 2 to Day 6) of infant series</time_frame>
    <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Systemic Events Within 5 Days After Dose 3 in MDV and SDS Group</measure>
    <time_frame>Within 5 days after Dose 3 (Day 2 to Day 6) of infant series</time_frame>
    <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Infant Series</measure>
    <time_frame>Dose 1 up to 28 to 42 days after dose 3</time_frame>
    <description>An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Dose 1</measure>
    <time_frame>Informed consent up to Dose 1</time_frame>
    <description>An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse events were also reported in participants who provided consent but were not randomized in this study. The data of these participants has been reported under 'Screened Only' arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Serotype-Specific Opsonophagocytic Activity (OPA) Titer &gt;= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Percentage of participants achieving OPA Titer &gt;= lower limit of quantitation (LLOQ) along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here &quot;n&quot;= Number of participants with an antibody titer ≥ LLOQ for the given serotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Antibody geometric mean titers as measured by OPA assay for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMTs were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. Here &quot;n&quot;= participants evaluable =specified category.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Pneumococcal Vaccines</condition>
  <arm_group>
    <arm_group_label>Multidose Vial Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-Dose Syringe Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.</description>
    <arm_group_label>Multidose Vial Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.</description>
    <arm_group_label>Single-Dose Syringe Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 42 to 70 days at enrollment.

          -  Determined by medical history, physical examination, and clinical judgment to be
             eligible for the study

          -  Weight of 3.5 kg or greater at the time of enrollment

        Exclusion Criteria:

          -  Previous vaccination with licensed or investigational pneumococcal vaccine.

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Contraindication to vaccination with pneumococcal conjugate vaccine.

          -  Receipt of blood products or gamma-globulin since birth
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>70 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Council Unit, The Gambia</name>
      <address>
        <city>Fajara</city>
        <state>The Gambia, West Africa</state>
        <zip>000273</zip>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fajikunda Major Health Centre</name>
      <address>
        <city>Ksmd</city>
        <state>The Gambia</state>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Gambia</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4671001&amp;StudyName=13vPnC%20Multidose%20Vial%20Safety%2C%20Tolerability%20and%20Immunogenicity%20Study%20in%20Healthy%20Infants.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <results_first_submitted>February 27, 2015</results_first_submitted>
  <results_first_submitted_qc>February 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2015</results_first_posted>
  <last_update_submitted>February 27, 2015</last_update_submitted>
  <last_update_submitted_qc>February 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevenar 13</keyword>
  <keyword>13vPnC</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Total number of participants screened were 526, out of which 500 were enrolled in the study. The study was conducted in Gambia which started on 09 January 2014 and completed on 01 September 2014.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC Multi-dose Vial (MDV)</title>
          <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
        </group>
        <group group_id="P2">
          <title>13vPnC Single-Dose Syringe (SDS)</title>
          <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>13vPnC Multi-dose Vial (MDV)</title>
          <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
        </group>
        <group group_id="B2">
          <title>13vPnC Single-Dose Syringe (SDS)</title>
          <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="250"/>
            <count group_id="B2" value="250"/>
            <count group_id="B3" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="8.6"/>
                    <measurement group_id="B2" value="56.9" spread="8.8"/>
                    <measurement group_id="B3" value="57.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (&gt;=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group</title>
        <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here “n”= participants with valid and determinate IgG concentration to the given serotype.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable immunogenicity population: eligible participants who received vaccine (as randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (&gt;=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group</title>
          <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here “n”= participants with valid and determinate IgG concentration to the given serotype.</description>
          <population>Evaluable immunogenicity population: eligible participants who received vaccine (as randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=245,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="96.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="92.6" upper_limit="98.0"/>
                    <measurement group_id="O2" value="97.1" lower_limit="94.2" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=243,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="93.1" upper_limit="98.3"/>
                    <measurement group_id="O2" value="97.5" lower_limit="94.7" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="91.6" upper_limit="97.4"/>
                    <measurement group_id="O2" value="95.1" lower_limit="91.6" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="95.3" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.4" lower_limit="95.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="94.7" upper_limit="99.1"/>
                    <measurement group_id="O2" value="98.4" lower_limit="95.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="97.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="98.0" lower_limit="95.3" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.8" lower_limit="96.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="93.7" upper_limit="98.6"/>
                    <measurement group_id="O2" value="97.1" lower_limit="94.2" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="92.6" upper_limit="98.0"/>
                    <measurement group_id="O2" value="95.9" lower_limit="92.6" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>1.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Exact 2-sided confidence interval (based on Chan &amp; Zhang) for the difference in proportions, 13vPnC multidose vial (MDV) – 13vPnC single-dose syringe (SDS), expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percentage difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody was demonstrated if the lower bound of the 2-sided, 97.5% confidence interval, computed using the Chan and Zhang procedure, for the difference in proportions (13vPnC MDV – 13vPnC SDS) was greater than -0.10.</non_inferiority_desc>
            <param_type>percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series for Each Vaccine Group</title>
        <description>Antibody GMC for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations. Here “n”= participants with valid and determinate IgG concentration to the given serotype.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable immunogenicity population: eligible participants who received vaccine (as randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series for Each Vaccine Group</title>
          <description>Antibody GMC for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the concentrations. Here “n”= participants with valid and determinate IgG concentration to the given serotype.</description>
          <population>Evaluable immunogenicity population: eligible participants who received vaccine (as randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="4.11" upper_limit="5.12"/>
                    <measurement group_id="O2" value="4.45" lower_limit="4.01" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=245,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="1.29" upper_limit="1.49"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.62" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" lower_limit="4.84" upper_limit="5.81"/>
                    <measurement group_id="O2" value="5.28" lower_limit="4.76" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.79" upper_limit="2.22"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.79" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=243,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="2.02" upper_limit="2.50"/>
                    <measurement group_id="O2" value="2.19" lower_limit="1.96" upper_limit="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" lower_limit="2.91" upper_limit="4.02"/>
                    <measurement group_id="O2" value="3.24" lower_limit="2.77" upper_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="3.59" upper_limit="4.27"/>
                    <measurement group_id="O2" value="4.18" lower_limit="3.83" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.56" upper_limit="3.13"/>
                    <measurement group_id="O2" value="2.75" lower_limit="2.49" upper_limit="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="4.06" upper_limit="5.63"/>
                    <measurement group_id="O2" value="4.96" lower_limit="4.27" upper_limit="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" lower_limit="3.17" upper_limit="3.79"/>
                    <measurement group_id="O2" value="2.72" lower_limit="2.46" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" lower_limit="5.70" upper_limit="7.38"/>
                    <measurement group_id="O2" value="6.44" lower_limit="5.66" upper_limit="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" lower_limit="4.59" upper_limit="5.86"/>
                    <measurement group_id="O2" value="5.00" lower_limit="4.43" upper_limit="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=245,244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" lower_limit="2.30" upper_limit="2.97"/>
                    <measurement group_id="O2" value="2.17" lower_limit="1.92" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.28</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Ratio of GMCs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale; CIs for the ratio are back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for a given antibody serotype was declared if lower bound of the 2-sided, 97.5% confidence interval for the geometric mean concentration ratio (GMC MDV /GMC SDS) was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.20</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Local Reaction Within 5 Days After Dose 1 in MDV and SDS Group</title>
        <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 5 days after Dose 1(Day 2 to Day 6) of the infant series</time_frame>
        <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Local Reaction Within 5 Days After Dose 1 in MDV and SDS Group</title>
          <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Local Reaction Within 5 Days After Dose 2 in MDV and SDS Group</title>
        <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 5 days after Dose 2 (Day 2 to Day 6) of the infant series</time_frame>
        <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days and 'n' = participants whose response was “Yes” for any day or “No” for all days for specified local reaction.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Local Reaction Within 5 Days After Dose 2 in MDV and SDS Group</title>
          <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days and 'n' = participants whose response was “Yes” for any day or “No” for all days for specified local reaction.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Any (n=248, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Mild (n=248, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Moderate (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Severe (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Local Reaction Within 5 Days After Dose 3 in MDV and SDS Group</title>
        <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 5 days after Dose 3 (Day 2 to Day 6) of the infant series</time_frame>
        <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Local Reaction Within 5 Days After Dose 3 in MDV and SDS Group</title>
          <description>Local reactions were reported within 5 days (day 2 to day 6) using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurt if gently touched; Moderate (hurt if gently touched with crying); Severe (caused limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.1 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Systemic Events Within 5 Days After Dose 1 in MDV and SDS Group</title>
        <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 5 days after Dose 1 (Day 2 to Day 6) of infant series</time_frame>
        <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days. ‘n’ included participants whose response was “Yes” for any day or “No” for all days for specified systemic event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Systemic Events Within 5 Days After Dose 1 in MDV and SDS Group</title>
          <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days. ‘n’ included participants whose response was “Yes” for any day or “No” for all days for specified systemic event.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38.0 degree C (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.0 but &lt;=39.0 degrees C (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;39.0 but &lt;=40.0 degrees C (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40.0 degrees C (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Any (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Moderate (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Severe (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any (n=249, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Mild (n=249, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Moderate (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Severe (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Any (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Mild (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Moderate (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Severe (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication (n=248, 250)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Systemic Events Within 5 Days After Dose 2 in MDV and SDS Group</title>
        <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 5 days after Dose 2 (Day 2 to Day 6) of infant series</time_frame>
        <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days. ‘n’ included participants whose response was “Yes” for any day or “No” for all days for specified systemic event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Systemic Events Within 5 Days After Dose 2 in MDV and SDS Group</title>
          <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days. ‘n’ included participants whose response was “Yes” for any day or “No” for all days for specified systemic event.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38.0 degree C (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.0 but &lt;=39.0 degrees C (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;39.0 but &lt;=40.0 degrees C (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40.0 degrees C (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Any(n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Moderate (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Severe (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any (n=248, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Mild (n=248, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Moderate (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Severe (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Any (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Mild (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Moderate (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Severe (n=247, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication (n=248, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Systemic Events Within 5 Days After Dose 3 in MDV and SDS Group</title>
        <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 5 days after Dose 3 (Day 2 to Day 6) of infant series</time_frame>
        <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days. ‘n’ included participants whose response was “Yes” for any day or “No” for all days for specified systemic event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Systemic Events Within 5 Days After Dose 3 in MDV and SDS Group</title>
          <description>Systemic events (any fever greater than or equal to [&gt;=] 38.0 degrees Celsius [C], decreased appetite was scaled as; Moderate (decreased oral intake); Severe (refusal to feed). Irritability scaled as; Mild (easily consolable); Moderate (requiring increased attention); Severe (Inconsolable, crying that cannot be comforted). Increased sleep was scale as; mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (Disabling not interested in usual daily activity) and use of antipyretic medication were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population included participants who received at least 1 dose of study vaccine. ‘N’ (number of participants analyzed) included participants whose response was “Yes” for any day or “No” for all days. ‘n’ included participants whose response was “Yes” for any day or “No” for all days for specified systemic event.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38.0 degree C (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.0 but &lt;=39.0 degrees C (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;39.0 but &lt;=40.0 degrees C (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40.0 degrees C (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Any (n=246, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Moderate (n=246, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite: Severe (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Any (n=246, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Mild (n=246, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Moderate (n=246, 242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability: Severe (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Any (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Mild (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Moderate (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep: Severe (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication (n=246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Infant Series</title>
        <description>An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state</description>
        <time_frame>Dose 1 up to 28 to 42 days after dose 3</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Infant Series</title>
          <description>An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 to 42 days after last dose that were absent before treatment or that worsened relative to pretreatment state</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Dose 1</title>
        <description>An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse events were also reported in participants who provided consent but were not randomized in this study. The data of these participants has been reported under ‘Screened Only’ arm.</description>
        <time_frame>Informed consent up to Dose 1</time_frame>
        <population>Safety population: participants who received at least 1 dose of study vaccine. Here “N”= participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Screened Only</title>
            <description>Participants who were screened for this study but were not randomized, assessed between signing of informed consent form and before randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Dose 1</title>
          <description>An AE was any untoward medical occurrence in a participants who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Adverse events were also reported in participants who provided consent but were not randomized in this study. The data of these participants has been reported under ‘Screened Only’ arm.</description>
          <population>Safety population: participants who received at least 1 dose of study vaccine. Here “N”= participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Serotype-Specific Opsonophagocytic Activity (OPA) Titer &gt;= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series</title>
        <description>Percentage of participants achieving OPA Titer &gt;= lower limit of quantitation (LLOQ) along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here “n”= Number of participants with an antibody titer ≥ LLOQ for the given serotype.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable immunogenicity population:participants who received vaccine (randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations. OPA analysis was performed in a subset of randomly selected participants from each group.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Serotype-Specific Opsonophagocytic Activity (OPA) Titer &gt;= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series</title>
          <description>Percentage of participants achieving OPA Titer &gt;= lower limit of quantitation (LLOQ) along with 95% CI for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Exact 2-sided confidence interval (Clopper and Pearson) based on the observed proportion of participants. Here “n”= Number of participants with an antibody titer ≥ LLOQ for the given serotype.</description>
          <population>Evaluable immunogenicity population:participants who received vaccine (randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations. OPA analysis was performed in a subset of randomly selected participants from each group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="64.0" upper_limit="78.5"/>
                    <measurement group_id="O2" value="79.4" lower_limit="72.3" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=160,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="95.6" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=159,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=160,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="76.4" upper_limit="88.6"/>
                    <measurement group_id="O2" value="85.5" lower_limit="79.1" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=160,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=156,155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="92.7" upper_limit="99.0"/>
                    <measurement group_id="O2" value="96.8" lower_limit="92.6" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=158,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" lower_limit="72.6" upper_limit="85.7"/>
                    <measurement group_id="O2" value="75.0" lower_limit="67.6" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=157,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="74.6" upper_limit="87.3"/>
                    <measurement group_id="O2" value="89.4" lower_limit="83.5" upper_limit="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=160,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="91.2" upper_limit="98.2"/>
                    <measurement group_id="O2" value="97.5" lower_limit="93.7" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=158,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="88.7" upper_limit="96.9"/>
                    <measurement group_id="O2" value="94.3" lower_limit="89.5" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="92.0" upper_limit="98.6"/>
                    <measurement group_id="O2" value="97.5" lower_limit="93.7" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.2</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-7.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC MDV – 13vPnC SDS, expressed as a percentage was analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>percent difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series</title>
        <description>Antibody geometric mean titers as measured by OPA assay for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMTs were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. Here “n”= participants evaluable =specified category.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable immunogenicity population:participants who received vaccine (randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations. OPA analysis was performed in a subset of randomly selected participants from each group.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Multi-dose Vial (MDV)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) with 2-phenoxyethanol (2-PE) in MDV intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Single-Dose Syringe (SDS)</title>
            <description>Participants received three doses of 0.5 milliliter (mL) of 13-valent pneumococcal conjugate vaccine (13vPnC) without 2-phenoxyethanol (2-PE) in SDS intramuscularly at 8, 12 and 16 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After the Infant Series</title>
          <description>Antibody geometric mean titers as measured by OPA assay for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F 9V, 14, 18C, 19A, 19F and 23F) are presented. GMTs were calculated using all participants with available data for the specified blood draw. CIs were back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers. Here “n”= participants evaluable =specified category.</description>
          <population>Evaluable immunogenicity population:participants who received vaccine (randomized) at all 3 doses, had blood drawn within protocol-specified time frames, had at least 1 valid and determinate assay result for proposed analysis, had no major protocol violations. OPA analysis was performed in a subset of randomly selected participants from each group.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="39.0" upper_limit="58.0"/>
                    <measurement group_id="O2" value="52" lower_limit="43.2" upper_limit="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n=160,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="87.3" upper_limit="108.8"/>
                    <measurement group_id="O2" value="122" lower_limit="110.1" upper_limit="135.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n=159,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1666" lower_limit="1412.3" upper_limit="1966.3"/>
                    <measurement group_id="O2" value="1492" lower_limit="1285.2" upper_limit="1732.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n=160,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="67.7" upper_limit="92.4"/>
                    <measurement group_id="O2" value="80" lower_limit="69.1" upper_limit="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n=160,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1690" lower_limit="1460.5" upper_limit="1955.9"/>
                    <measurement group_id="O2" value="1968" lower_limit="1698.5" upper_limit="2279.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n=156,155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1990" lower_limit="1611.7" upper_limit="2456.9"/>
                    <measurement group_id="O2" value="2014" lower_limit="1639.1" upper_limit="2475.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2891" lower_limit="2565.4" upper_limit="3258.5"/>
                    <measurement group_id="O2" value="3450" lower_limit="3014.7" upper_limit="3947.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n=158,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="709" lower_limit="600.5" upper_limit="836.2"/>
                    <measurement group_id="O2" value="706" lower_limit="597.0" upper_limit="835.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n=157,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567" lower_limit="415.4" upper_limit="773.5"/>
                    <measurement group_id="O2" value="786" lower_limit="607.8" upper_limit="1015.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2792" lower_limit="2387.5" upper_limit="3264.8"/>
                    <measurement group_id="O2" value="1605" lower_limit="1352.0" upper_limit="1904.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n=160,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305" lower_limit="256.2" upper_limit="362.9"/>
                    <measurement group_id="O2" value="329" lower_limit="284.8" upper_limit="379.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n=158,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430" lower_limit="357.6" upper_limit="517.1"/>
                    <measurement group_id="O2" value="470" lower_limit="391.4" upper_limit="565.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n=159,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="918" lower_limit="729.0" upper_limit="1156.4"/>
                    <measurement group_id="O2" value="998" lower_limit="810.6" upper_limit="1229.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Ratio of GMTs, MDV to SDS, was calculated by back transforming the mean difference between the vaccine groups on the logarithmic scale. CIs for the ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC MDV – 13vPnC SDS).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs)/serious AEs (SAEs): recorded from signing of informed consent form to 28 to 42 days after dose 3. Pre-specified AEs were recorded in an electronic diary: local reactions, systemic events (Day 2 to Day 6 after each vaccination)</time_frame>
      <desc>SAEs, AEs grouped by system organ class and summarized. AEs included AEs collected in electronic diary (local, systemic reactions;systematic assessment), events collected on case report form at each visit (non-systematic assessment). AEs also reported in participants who provided consent but were not randomized (reported under ‘Screened Only’ arm).</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC MDV: Informed Consent to Dose 1</title>
          <description>Participants who were randomized to receive 13vPnC (PF-06414256) MDV at 8, 12, and 16 weeks of age, assessed between signing of informed consent and before Dose 1.</description>
        </group>
        <group group_id="E2">
          <title>13vPnC SDS: Informed Consent to Dose 1</title>
          <description>Participants who were randomized to receive 13vPnC (PF-05208760) SDS at 8, 12, and 16 weeks of age, assessed between signing of informed consent and before Dose 1.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC MDV: After Dose 1</title>
          <description>Participants who received single 0.5 mL dose of 13vPnC (PF-06414256) using MDV intramuscularly into the anterolateral thigh muscle of the left leg at 8 weeks of age, assessed after Dose 1 and before Dose 2.</description>
        </group>
        <group group_id="E4">
          <title>13vPnC SDS: After Dose 1</title>
          <description>Participants who received single 0.5 mL dose of 13vPnC (PF-05208760) using SDS intramuscularly into the anterolateral thigh muscle of the left leg at 8 weeks of age, assessed after Dose 1 and before Dose 2.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC MDV: After Dose 2</title>
          <description>Participants who received two 0.5 mL doses of 13vPnC (PF-06414256) using MDV intramuscularly into the anterolateral thigh muscle of the left leg 8, 12 weeks of age, assessed after Dose 2 and before Dose 3.</description>
        </group>
        <group group_id="E6">
          <title>13vPnC SDS: After Dose 2</title>
          <description>Participants who received two 0.5 mL doses of 13vPnC (PF-05208760) using SDS intramuscularly into the anterolateral thigh muscle of the left leg 8, 12 weeks of age, assessed after Dose 2 and before Dose 3.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC MDV: After Dose 3</title>
          <description>Participants who received all three 0.5mL doses of 13vPnC (PF-06414256) using MDV intramuscularly into the anterolateral thigh muscle of the left leg at 8 weeks of age, assessed after Dose 3 and up to blood draw at 4 weeks.</description>
        </group>
        <group group_id="E8">
          <title>13vPnC SDS: After Dose 3</title>
          <description>Participants who received all three 0.5mL doses of 13vPnC (PF-05208760) using SDS intramuscularly into the anterolateral thigh muscle of the left leg at 8 weeks of age, assessed after Dose 3 and up to blood draw at 4 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Screened Only</title>
          <description>Participants who were screened for this study but were not randomized, assessed between signing of informed consent form and before randomization.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="107" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="114" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="99" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="97" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="102" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vaccination site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;=38.0 degree C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;=38.0 but &lt;=39.0 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;39.0 but &lt;=40.0 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;40.0 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="242"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="242"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="93" subjects_at_risk="248"/>
                <counts group_id="E6" subjects_affected="83" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="83" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="92" subjects_at_risk="243"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="248"/>
                <counts group_id="E6" subjects_affected="67" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="71" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="74" subjects_at_risk="242"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="242"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Tinea faciei</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Growth retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Umbilical granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="248"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="248"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

